Skip to main content

Managing ADPKD

Monitoring disease progression is an important part of managing autosomal dominant polycystic kidney disease (ADPKD)

  • The majority of patients (~85%) suffer from PKD1 mutations, which generally result in a more severe form of ADPKD. They are typically younger at diagnosis and have a faster progression to end-stage renal disease (ESRD).2

While symptoms may be scarce in early-stage disease, the kidneys continue to increase in volume and damage continues to progress.1,2

Because the rate at which ADPKD advances can be variable, monitoring progression is one way to help manage the disease.1

Identifying rapid renal disease progression

There are a number of early and reliable markers of rapid renal disease progression3,4:

  • PKD1 mutations

  • Increased TKV

  • Early-onset hypertension

  • Early and multiple episodes of gross hematuria

  • Glomerular hyperfiltration at a young age

  • Reduction in renal blood flow at a young age

  • Increased serum uric acid level

  1. Braun WE. Autosomal dominant polycystic kidney disease: emerging concepts of pathogenesis and new treatments. Cleve Clin J Med. 2009;76(2):97-104.

  2. Chapin HC, Caplan MJ. The cell biology of polycystic kidney disease. J Cell Biol. 2010;191(4):701-710.

  3. Schrier RW. Randomized intervention studies in human polycystic kidney and liver disease. J Am Soc Nephrol. 2010;21(6):891-893.

  4. Helal I, Reed B, Schrier RW. Emergent early markers of renal progression in autosomal-dominant polycystic kidney disease patients: implications for prevention and treatment. Am J Nephrol. 2012;36(2):162-167.